Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib Continuation Study in ALK+ or ROS1+ NSCLC
NCT05144997Phase 4Active, not recruiting
- Sponsor
- Pfizer
- Start
- Dec 2021
- Primary completion
- Oct 2029
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 8
01
Overview
A Phase 4 trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Dec 2021; status: active, not recruiting.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05144997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05144997.